Abstract:Cornea blindness is still treated mainly by corneal transplantation, using donated allograft human corneas. However, a severe global shortfall leaves an estimated 12.7 million patients on waiting lists despite methods of using one cornea for two different partial‐thickness grafts. Even more individuals are not on waiting lists because they have no access to transplantation in their countries or regions. However, even if donor tissues were readily available, patients with inflamed, severely damaged corneas are at high risk of rejecting conventional transplantation. Various solutions have been proposed as alternatives to corneal allografting, including the development of keratoprostheses and stem cell grafting. We posited using cell‐free implants that mimic the extracellular matrix of the human cornea to recapitulate the environment during corneal development and stimulate the endogenous cells within the patient's eyes to affect regeneration. We used cell‐free corneal implants made from chemically crosslinked recombinant human collagen to promote in situ tissue regeneration in pathologic corneas, including high‐risk ones. We successfully developed and tested recombinant human solid collagen‐based implants that promoted stable regeneration in inflamed human patient corneas based on phosphorylcholine (MPC). However, solid corneas require a full operating theatre and staffing, which is costly and not accessible to more remote regions in Canada and globally. Burns and severe infections that can lead to perforations are medical emergencies that require immediate methods to seal the eye. In many centres, cyanoacrylate glue is used as a sealant, but this is toxic and kills surrounding cells, often necessitating follow‐on transplantation. We developed a synthetic, biocompatible, and adhesive liquid hydrogel (LiQD Cornea), which would replace these toxic cyanoacrylate glues. LiQD cornea is applied as a liquid but quickly adheres and gels within corneal tissue defects like a dental filling. It can be used to fill ulcers and other damaged areas. Then its similarity at a molecular level to a natural tissue framework promotes tissue regeneration, treating corneal perforations effectively without transplantation. Further, due to the synthetic nature of the material, risks associated with disease transmission are reduced compared to natural products. We see LiQD Cornea potentially used in outpatient clinics instead of operating theatres, maximizing practicality and minimizing health care costs.

Corneal Regenerative Medicine: Corneal Substitutes For Transplantation

Biomaterials for Corneal Bioengineering

3D bioprinting for artificial cornea: Challenges and perspectives.

Integrated 3D Bioprinting-Based Geometry-Control Strategy for Fabricating Corneal Substitutes

[ARTIFICIAL CORNEA: FROM THE BEGINNING TO THE FUTURE]

Regenerative Therapy for Corneal Scarring Disorders

Corneal Stromal Regeneration: Current Status and Future Therapeutic Potential

Biomaterials-enabled Cornea Regeneration in Patients at High Risk for Rejection of Donor Tissue Transplantation

Artificial corneas ‐ Recent developments

An Overview of Corneal Transplantation in the Past Decade

Corneal regeneration strategies: From stem cell therapy to tissue engineered stem cell scaffolds

Evaluation of Corneal Cell Growth on Tissue Engineering Materials As Artificial Cornea Scaffolds.

The landscape of clinical trials in corneal regeneration: A systematic review of tissue engineering approaches in corneal disease

3D Bioprinting As a Prospective Therapeutic Strategy for Corneal Limbal Epithelial Stem Cell Deficiency

In situ Tissue Regeneration in the Cornea from Bench to Bedside

Synthetic solutions for re‐growing human corneas

Use of discarded corneo-scleral rims to create cornea-like tissue

Biologicals and Biomaterials for Corneal Regeneration and Vision Restoration in Limbal Stem Cell Deficiency

Advances in tissue engineering and 3D bioprinting for corneal regeneration

Artificial cornea and related materials

Stem Cell Therapy for Corneal Regeneration Medicine and Contemporary Nanomedicine for Corneal Disorders